Inogen (NASDAQ:INGN) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Inogen (NASDAQ:INGN) in a research note released on Wednesday morning, Benzinga reports.

Separately, William Blair raised Inogen from a market perform rating to an outperform rating in a research report on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus price target of $7.00.

Inogen Price Performance

Shares of Inogen stock traded up $0.03 on Wednesday, hitting $8.27. 74,297 shares of the company’s stock traded hands, compared to its average volume of 524,620. Inogen has a one year low of $4.13 and a one year high of $11.98. The company has a fifty day moving average of $7.11 and a two-hundred day moving average of $6.51. The company has a market capitalization of $194.73 million, a price-to-earnings ratio of -1.87 and a beta of 1.10.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.14. The firm had revenue of $78.03 million for the quarter, compared to analysts’ expectations of $73.67 million. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.63) EPS. Equities research analysts anticipate that Inogen will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INGN. Tower Research Capital LLC TRC boosted its stake in Inogen by 84.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 2,419 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Inogen by 2,918.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 7,646 shares during the last quarter. Paradigm Capital Management Inc. NY bought a new stake in shares of Inogen during the 3rd quarter valued at about $52,000. SG Americas Securities LLC bought a new stake in shares of Inogen during the 3rd quarter valued at about $52,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Inogen during the 3rd quarter valued at about $79,000. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.